Sutro Biopharma (STRO) Stock Forecast & Price Target

Compare

716 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

STRO Analyst Ratings

Hold

1 Buy

1 Hold

1 Sell

Based on 3 analysts giving stock ratings to

Sutro

Biopharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

STRO Stock 12 Month Forecast

Average Price Target

$13.67

▼(-41.81% Downside)

Based on 3 Wall Street analysts offering 12 month price targets for Sutro Biopharma in the last 3 months. The average price target is $13.67 with a high forecast of $23.00 and a low forecast of $8.00. The average price target represents a -41.81% change from the last price of $23.49.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","10":"$10","16":"$16","22":"$22","28":"$28"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$23.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$13.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,10,16,22,28],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.57,12.44923076923077,13.32846153846154,14.207692307692309,15.086923076923078,15.966153846153848,16.845384615384617,17.724615384615383,18.603846153846156,19.483076923076922,20.362307692307695,21.24153846153846,22.12076923076923,{"y":23,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.57,11.731538461538461,11.893076923076924,12.054615384615385,12.216153846153846,12.377692307692309,12.53923076923077,12.70076923076923,12.862307692307692,13.023846153846154,13.185384615384615,13.346923076923076,13.508461538461539,{"y":13.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,11.57,11.295384615384616,11.02076923076923,10.746153846153847,10.471538461538461,10.196923076923078,9.922307692307692,9.647692307692308,9.373076923076923,9.098461538461539,8.823846153846153,8.54923076923077,8.274615384615384,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":27.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.9,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.953,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.048,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.1,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.571,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":9.03,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 37, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.2,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 50, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.015,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 71, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.57,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 61, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$23.00

Average Price Target$13.67

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tazeen Ahmad

Bank of America Securities

Sell

-65.94%

Downside

Reiterated

01/27/26

Sutro Biopharma (STRO) Gets a Sell from Bank of America Securities

Reni Benjamin

Citizens JMP

$23

Buy

-2.09%

Downside

Upgraded

01/20/26

Sutro Biopharma upgraded to Outperform from Market Perform at CitizensSutro Biopharma upgraded to Outperform from Market Perform at Citizens

Andres Y. Maldonado

H.C. Wainwright

$20→$10

Hold

-57.43%

Downside

Reiterated

12/22/25

Sutro Biopharma: Transition to STRO-004–Driven Clinical Execution Warrants Hold as Long-Term Upside Meets Near-Term Uncertainty

James Shin

Deutsche Bank

$5→$51

Buy

117.11%

Upside

Reiterated

12/17/25

Sutro Biopharma price target raised to $51 from $5 at Deutsche BankSutro Biopharma price target raised to $51 from $5 at Deutsche Bank

Eva Fortea Verdejo

Wells Fargo

$3→$8

Hold

-65.94%

Downside

Reiterated

12/12/25

Wells Fargo Reaffirms Their Hold Rating on Sutro Biopharma (STRO)

Edward Tenthoff

Piper Sandler

$20

Buy

-14.86%

Downside

Reiterated

12/04/25

Sutro Biopharma (STRO) Receives a Buy from Piper Sandler

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

11/11/25

Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (NASDAQ: MDGL), Doximity (NYSE: DOCS) and Sutro Biopharma (NASDAQ: STRO)

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

11/06/25

Analysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Black Diamond Therapeutics (BDTX)

Roger Song

Jefferies

$70→$40

Buy

70.29%

Upside

Reiterated

09/09/25

Sutro Biopharma price target lowered to $4 from $7 at JefferiesSutro Biopharma price target lowered to $4 from $7 at Jefferies

David Nierengarten

Wedbush

$20

Hold

-14.86%

Downside

Reiterated

05/09/25

Sutro Biopharma (STRO) Receives a Hold from Wedbush

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tazeen Ahmad

Bank of America Securities

Sell

-65.94%

Downside

Reiterated

01/27/26

Sutro Biopharma (STRO) Gets a Sell from Bank of America Securities

Reni Benjamin

Citizens JMP

$23

Buy

-2.09%

Downside

Upgraded

01/20/26

Sutro Biopharma upgraded to Outperform from Market Perform at CitizensSutro Biopharma upgraded to Outperform from Market Perform at Citizens

Andres Y. Maldonado

H.C. Wainwright

$20→$10

Hold

-57.43%

Downside

Reiterated

12/22/25

Sutro Biopharma: Transition to STRO-004–Driven Clinical Execution Warrants Hold as Long-Term Upside Meets Near-Term Uncertainty

James Shin

Deutsche Bank

$5→$51

Buy

117.11%

Upside

Reiterated

12/17/25

Sutro Biopharma price target raised to $51 from $5 at Deutsche BankSutro Biopharma price target raised to $51 from $5 at Deutsche Bank

Eva Fortea Verdejo

Wells Fargo

$3→$8

Hold

-65.94%

Downside

Reiterated

12/12/25

Wells Fargo Reaffirms Their Hold Rating on Sutro Biopharma (STRO)

Edward Tenthoff

Piper Sandler

$20

Buy

-14.86%

Downside

Reiterated

12/04/25

Sutro Biopharma (STRO) Receives a Buy from Piper Sandler

Asthika Goonewardene

Truist Financial

―

Buy

―

Reiterated

11/11/25

Analysts Conflicted on These Healthcare Names: Madrigal Pharmaceuticals (NASDAQ: MDGL), Doximity (NYSE: DOCS) and Sutro Biopharma (NASDAQ: STRO)

Tara Bancroft

TD Cowen

―

Buy

―

Reiterated

11/06/25

Analysts Are Bullish on Top Healthcare Stocks: Sutro Biopharma (STRO), Black Diamond Therapeutics (BDTX)

Roger Song

Jefferies

$70→$40

Buy

70.29%

Upside

Reiterated

09/09/25

Sutro Biopharma price target lowered to $4 from $7 at JefferiesSutro Biopharma price target lowered to $4 from $7 at Jefferies

David Nierengarten

Wedbush

$20

Hold

-14.86%

Downside

Reiterated

05/09/25

Sutro Biopharma (STRO) Receives a Hold from Wedbush

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sutro Biopharma

3 Months

xxx

Success Rate

8/19 ratings generated profit

Average Return

-1.81%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.11% of your transactions generating a profit, with an average return of -1.81% per trade.

1 Year

Edward TenthoffPiper Sandler

Success Rate

7/19 ratings generated profit

Average Return

+1.57%

reiterated a buy rating 3 months ago

Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 36.84% of your transactions generating a profit, with an average return of +1.57% per trade.

2 Years

xxx

Success Rate

4/19 ratings generated profit

Average Return

-20.88%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 21.05% of your transactions generating a profit, with an average return of -20.88% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

STRO Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, STRO has received 7 Buy Ratings, 61 Hold Ratings, and 12 Sell Ratings. STRO average Analyst price target in the past 3 months is 13.67.

Each month's total comprises the sum of three months' worth of ratings.

STRO Financial Forecast

STRO Earnings Forecast

Currently, no earnings data available.

STRO Sales Forecast

Currently, no sales data available.

STRO Stock Forecast FAQ

What is STRO’s average 12-month price target, according to analysts?

Based on analyst ratings, Sutro Biopharma Inc’s 12-month average price target is 13.67.

What is STRO’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for STRO, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is STRO a Buy, Sell or Hold?

Sutro Biopharma Inc has a consensus rating of Hold which is based on 1 buy ratings, 1 hold ratings and 1 sell ratings.

What is Sutro Biopharma Inc’s price target?

The average price target for Sutro Biopharma Inc is 13.67. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $23.00 ,the lowest forecast is $8.00. The average price target represents -41.81% Decrease from the current price of $23.49.

What do analysts say about Sutro Biopharma Inc?

Sutro Biopharma Inc’s analyst rating consensus is a Hold. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of STRO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Sutro Biopharma (STRO) Stock Forecast & Price Target

STRO Analyst Ratings

STRO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Sutro Biopharma

STRO Analyst Recommendation Trends

STRO Financial Forecast

STRO Earnings Forecast

STRO Sales Forecast

STRO Stock Forecast FAQ

Detailed List of Analyst Forecasts